Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124,493 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.
Peng Z, Liu T, Wei J, Wang A, He Y, Yang L, Zhang X, Fan N, Luo S, Li Z, Gu K, Lu J, Xu J, Fan Q, Xu R, Zhang L, Li E, Sun Y, Yu G, Bai C, Liu Y, Zeng J, Ying J, Liang X, Xu N, Gao C, Shu Y, Ma D, Dai G, Li S, Deng T, Cui Y, Fang J, Ba Y, Shen L. Peng Z, et al. Among authors: zhang l, zhang x. Cancer Commun (Lond). 2021 Nov;41(11):1173-1182. doi: 10.1002/cac2.12214. Epub 2021 Oct 19. Cancer Commun (Lond). 2021. PMID: 34665942 Free PMC article. Clinical Trial.
Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study.
Liang H, Song X, Zhang Y, Zhang S, Li F, Fang J, Li J, Liang L, Nie L, Ma K, Zhang L, Wang X, Xu J, Wei Y, Wang J, Song Q, Tian G, Mu Y, Gu Y, Yang L, Sun P, Zhong W, Zhao J, Xu Y, Chen M, Wang M. Liang H, et al. Among authors: zhang l, zhang s, zhang y. Thorac Cancer. 2019 Jul;10(7):1521-1532. doi: 10.1111/1759-7714.13090. Epub 2019 May 29. Thorac Cancer. 2019. PMID: 31144459 Free PMC article.
Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial.
Wei Z, Yang X, Ye X, Feng Q, Xu Y, Zhang L, Sun W, Dong Y, Meng Q, Li T, Wang C, Li G, Zhang K, Li P, Bi J, Xue G, Sun Y, Sheng L, Liu B, Yu G, Ren H, Wang J, Sun L, Chen S, Geng D, Zhang B, Xu X, Zhang L, Sun D, Xu X, Diao C, Huang G, Li W, Han X, Wang J, Meng M, Ni Y, Zheng A, Fan W, Li Y, Li F, Fan H, Zou Z, Li Q, Tian H. Wei Z, et al. Among authors: zhang l, zhang b, zhang k. Eur Radiol. 2020 May;30(5):2692-2702. doi: 10.1007/s00330-019-06613-x. Epub 2020 Feb 4. Eur Radiol. 2020. PMID: 32020400 Clinical Trial.
Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial.
Xu B, Zhang Q, Sun T, Li W, Teng Y, Hu X, Bondarenko I, Adamchuk H, Zhang L, Trukhin D, Wang S, Zheng H, Tong Z, Shparyk Y, Wang Q; HLX02-BC01 Investigators. Xu B, et al. Among authors: zhang l, zhang q. BioDrugs. 2021 May;35(3):337-350. doi: 10.1007/s40259-021-00475-w. Epub 2021 Apr 7. BioDrugs. 2021. PMID: 33826080 Free PMC article. Clinical Trial.
Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study.
Qin S, Li J, Bai Y, Shu Y, Li W, Yin X, Cheng Y, Sun G, Deng Y, Zhong H, Li Y, Qian X, Zhang L, Zhang J, Chen K, Kang W; HLX04-mCRC03 Investigators. Qin S, et al. Among authors: zhang l, zhang j. BioDrugs. 2021 Jul;35(4):445-458. doi: 10.1007/s40259-021-00484-9. Epub 2021 May 20. BioDrugs. 2021. PMID: 34014555 Free PMC article. Clinical Trial.
Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial.
Shi Y, Fang J, Hao X, Zhang S, Liu Y, Wang L, Chen J, Hu Y, Hang X, Li J, Liu C, Zhang Y, Wang Z, Hu Y, Gu K, Huang J, Zhang L, Shan J, Ouyang W, Zhao Y, Zhuang W, Yu Y, Zhao J, Zhang H, Lu P, Li W, Si M, Ge M, Geng H. Shi Y, et al. Among authors: zhang l, zhang s, zhang h, zhang y. Signal Transduct Target Ther. 2022 Jan 28;7(1):25. doi: 10.1038/s41392-021-00841-8. Signal Transduct Target Ther. 2022. PMID: 35087031 Free PMC article. Clinical Trial.
Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study.
Shi Y, Zhao Y, Yang S, Zhou J, Zhang L, Chen G, Fang J, Zhu B, Li X, Shu Y, Shi J, Zheng R, Wang D, Yu H, Huang J, Zhuang Z, Wu G, Zhang L, Guo Z, Greco M, Li X, Zhang Y. Shi Y, et al. Among authors: zhang l, zhang y. J Thorac Oncol. 2022 May;17(5):708-717. doi: 10.1016/j.jtho.2022.01.015. Epub 2022 Feb 15. J Thorac Oncol. 2022. PMID: 35181498 Free article. Clinical Trial.
Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma.
Guo LH, Zhang MF, Zhang HL, Zhou JY, Cai XH, Long Y, Guo QS, Yang N, Zhao J, Xie ZH, Jiang B, Zhu Y, Fan Y, Xie CY, Hu Y, Yao Y, Jia J, Li XL, Cui JW, Sui XZ, Lin W, Cheng Y, Wang HJ, Wang CL, Zhao MF, Qiao GB, Peng LJ, Yang L, Chen GY, Cai KC, Xu XH, Zhang LM, Feng GS, Zhou JM, Wu GW, Dong XR, Wang LF, Zhang HM, Gao YJ, Jiang QY, Cang SD, Yang ZX, Song X, Liu XQ, Zhu B, Chen FX, Hu CH, Chen X, Wu YL, Zhou Q. Guo LH, et al. Among authors: zhang hl, zhang hm, zhang mf, zhang lm. Front Oncol. 2020 Sep 15;10:1568. doi: 10.3389/fonc.2020.01568. eCollection 2020. Front Oncol. 2020. PMID: 33042801 Free PMC article.
124,493 results
You have reached the last available page of results. Please see the User Guide for more information.